CNS / Pain

Standard of care treatments in both CNS and Pain conditions currently target symptoms rather than the underlying cause of the disease. Significant limitations in therapeutic effect and tolerability issues also result in high rates of therapy discontinuation and unmet therapeutic need.  Therefore, new therapeutic classes due to launch in the near future are set to offer physicians additional treatment options for patients, where outcomes are sub-optimal and tolerability issues exist.

Real-world evidence generated via the CNS and Pain Disease Specific Programmes™ can provide market insights and understanding of the current landscape, as well as measure disease burden and identify areas of opportunity for new treatments.